FDA approves Sunovion schizophrenia drug
Sunovion Pharmaceuticals Inc. said that the US Food and Drug Administration has approved its Latuda drug candidate for the treatment of schizophrenia.
"Latuda is an oral, once-daily atypical antipsychotic, offering a first-line treatment option for patients with schizophrenia and is expected to be available in the US during the first quarter of 2011," Marlborough-based Sunovion said in a press release.
Schizophrenia affects about 2.4 million American adults, Sunovion noted in its press release.
Sunovion recently changed its name from Sepracor, a company known for its Lunesta sleep aid. A year ago, Sepracor was acquired by Dainippon Sumitomo Pharma Co., a Japanese drug maker. In July, Dainippon Sumitomo said it would change Sepracor's name to Sunovion on roughly the first anniversary of the sale, which recently occurred.
In a statement, Masayo Tada, president and chief executive of Dainippon Sumitomo, commented on Latuda, saying, "With this approval, we've taken another big step towards becoming a truly competitive global company by enhancing the presence of Sunovion in the United States."